Get a quote

We're excited to learn more about your project and provide you with a customized quote tailored to your needs. Please fill out the form below, and we'll get back to you as soon as possible.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Recombinant Influenza A H1N2 Neuraminidase (NA), N-His

Cat. No.VG9F110

Product TypeVeterinary Antigens

Size 100 μg

Product Overview

BioVenic's Recombinant Influenza A H1N2 Neuraminidase (NA), N-His is a recombinant protein expressed from HEK293 Cells. Its predicted molecular weight is 50.6 kDa. The purity is>85% (SDS-PAGE). The endotoxin level is <1 EU/μg (LAL).

Specifications

Type Recombinant Protein
Species Virus
Expression System HEK293 Cells
Purity >85% (SDS-PAGE)
Predicted Molecular Weight 50.6 kDa
Physical State Lyophilized
Formulation PBS, pH 7.4.

Target Information

Influenza A virus subtype H1N2 (A/H1N2) belongs to the species Influenza A virus, sometimes referred to as bird flu or swine flu. This subtype is currently endemic in pig populations and occasionally infects humans. Neuraminidase of influenza A and B viruses plays a critical role in the virus life cycle and is an important target of the host immune system.

Protein Influenza A H1N2 Neuraminidase (NA)
Protein Synonym Neuraminidase; NA
UniProt ID R4ZD61
EC No. 3.2.1.18

Shipping and Storage

This product is shipped with dry ice. Avoid repeated freezing and thawing. Store for 4 weeks at 2-8°C, for 12 months at -20°C or -80°C.

Documents

COA

To request a Certificate of Analysis, please enter the Lot No. in the search box. Note: Certificate of Analysis not available for kits.

The product is for research use only.
Not for commercial, prophylactic, diagnostic, or therapeutic applications.

User Note

  1. Always centrifuge tubes before opening. Avoid mixing by vortexing or pipetting. Aliquote the reconstituted solution to minimise freeze-thaw cycles.

References

  1. Creytens, Sarah et al. "Influenza Neuraminidase Characteristics and Potential as a Vaccine Target." Frontiers in immunology vol. 12 786617.
Inquiry Basket